Xilio Therapeutics (XLO) Shares Outstanding (2020 - 2026)

Xilio Therapeutics has disclosed Shares Outstanding (Entity) across 7 years of filings, most recently posting $19.4 million for Q2 2026.

• In Q2 2026, Shares Outstanding (Entity) rose 181.67% year-over-year to $19.4 million; the TTM figure through Jun 2026 stood at $19.4 million (up 181.67% YoY), while the FY2025 annual figure was $8.4 million, up 155.76% from the prior year.
• Shares Outstanding (Entity) came in at $19.4 million for Q2 2026 at Xilio Therapeutics, up from $16.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Entity) ranged from a high of $19.4 million in Q2 2026 to a low of $2.0 million in Q1 2022.
• Average Shares Outstanding (Entity) over 5 years is $5.3 million, with a median of $2.6 million recorded in 2024.
• Year-over-year, Shares Outstanding (Entity) soared 3689.73% in 2022 and increased 0.23% in 2023.
• Over 5 years, Shares Outstanding (Entity) stood at $2.0 million in 2022, then increased by 0.66% to $2.0 million in 2023, then jumped by 65.74% to $3.3 million in 2024, then surged by 155.76% to $8.4 million in 2025, then soared by 132.14% to $19.4 million in 2026.
• Per Business Quant data, the three most recent Shares Outstanding (Entity) figures were $19.4 million in Q2 2026, $16.3 million in Q1 2026, and $8.4 million in Q4 2025.